Fresenius Kabi Introduces IDACIO® (adalimumab-aacf) as its First Immunology Biosimilar in the United States

Fresenius Kabi, a global healthcare company specializing in medicines and technologies, has announced the availability of its first immunology biosimilar, IDACIO® (adalimumab-aacf), in the United States. IDACIO® is indicated for use in the treatment of chronic autoimmune diseases and is a biosimilar to Humira® (adalimumab). It is available in a self-administered prefilled syringe and pre-filled ..